Juan Jaen Sells 9,236 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 9,236 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $27.03, for a total value of $249,649.08. Following the transaction, the president owned 913,004 shares in the company, valued at approximately $24,678,498.12. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Arcus Biosciences Trading Up 2.0%

RCUS stock traded up $0.56 during midday trading on Wednesday, hitting $28.74. The company had a trading volume of 1,784,969 shares, compared to its average volume of 1,240,586. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of -9.04 and a beta of 0.85. Arcus Biosciences, Inc. has a 52 week low of $7.91 and a 52 week high of $29.85. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average price is $24.40 and its 200 day moving average price is $22.90.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm had revenue of $17.00 million during the quarter, compared to analysts’ expectations of $29.48 million. During the same period in the previous year, the firm earned ($1.14) earnings per share. The firm’s quarterly revenue was down 39.3% compared to the same quarter last year. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently added to or reduced their stakes in RCUS. California State Teachers Retirement System boosted its holdings in shares of Arcus Biosciences by 16.7% during the 1st quarter. California State Teachers Retirement System now owns 105,776 shares of the company’s stock valued at $2,285,000 after buying an additional 15,110 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Arcus Biosciences by 14.6% in the 1st quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock worth $102,000 after acquiring an additional 607 shares in the last quarter. Quantinno Capital Management LP lifted its position in Arcus Biosciences by 8.5% during the 1st quarter. Quantinno Capital Management LP now owns 17,295 shares of the company’s stock valued at $374,000 after acquiring an additional 1,349 shares during the period. SummitTX Capital L.P. grew its holdings in Arcus Biosciences by 17.4% in the first quarter. SummitTX Capital L.P. now owns 34,219 shares of the company’s stock worth $739,000 after purchasing an additional 5,076 shares during the period. Finally, Entropy Technologies LP purchased a new position in shares of Arcus Biosciences during the first quarter valued at approximately $294,000. Institutional investors own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

RCUS has been the subject of a number of analyst reports. Lifesci Capital initiated coverage on shares of Arcus Biosciences in a report on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price for the company. Wedbush increased their price objective on Arcus Biosciences from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. Citigroup raised their price target on Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, The Goldman Sachs Group upped their price objective on shares of Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.10.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.